Business Segments · Operating Income (Loss), Before Adjustments

Life Sciences: — Operating Income (Loss), Before Adjustments

STERIS Life Sciences: — Operating Income (Loss), Before Adjustments increased by 6.4% to $61.80M in Q4 2025 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ4 2024
Last reportedQ4 2025

How to read this metric

Provides a clear view of underlying operational trends; consistent growth indicates a healthy, stable business unit.

Detailed definition

This metric represents the raw operating performance of the Life Sciences segment before any non-recurring or special ad...

Peer comparison

Similar to 'Adjusted Operating Income' or 'Core Operating Profit' metrics used by peers to normalize segment performance.

Metric ID: ste_segment_life_sciences_operating_income_loss_before_adjustments

Historical Data

2 periods
 Q4 '24Q4 '25
Value$58.10M$61.80M
QoQ Change—+6.4%
YoY Change—+6.4%
Range$58.10M – $61.80M
Avg YoY Growth+6.4%
Median YoY Growth+6.4%

Similar Metrics at Other Companies

Agilent Technologies logo
Agilent TechnologiesAView metric
Agilent Technologies logo
Agilent TechnologiesAView metric
Labcorp Holdings logo
Labcorp HoldingsLHView metric
GLW
CorningGLWView metric
CVS Health logo
CVS HealthCVSView metric
Labcorp Holdings logo
Labcorp HoldingsLHView metric

Frequently Asked Questions

What is STERIS's life sciences: — operating income (loss), before adjustments?
STERIS (STE) reported life sciences: — operating income (loss), before adjustments of $61.80M in Q4 2025.
What does life sciences: — operating income (loss), before adjustments mean?
The core operating profit of the Life Sciences segment before accounting adjustments.